Platinum Investment Management Ltd. Reduces Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Platinum Investment Management Ltd. lessened its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 28.4% during the 4th quarter, Holdings Channel reports. The firm owned 87,874 shares of the company’s stock after selling 34,884 shares during the quarter. Structure Therapeutics comprises 1.4% of Platinum Investment Management Ltd.’s portfolio, making the stock its 15th largest holding. Platinum Investment Management Ltd.’s holdings in Structure Therapeutics were worth $6,112,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GPCR. Deutsche Bank AG purchased a new stake in Structure Therapeutics during the 4th quarter valued at about $58,503,000. Principal Financial Group Inc. boosted its stake in shares of Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after buying an additional 496,726 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Structure Therapeutics in the third quarter worth about $12,923,000. Orbimed Advisors LLC boosted its stake in shares of Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new stake in shares of Structure Therapeutics in the third quarter worth about $10,440,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

GPCR has been the topic of a number of recent research reports. BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Citizens Jmp lowered their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research note on Friday, February 27th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wolfe Research initiated coverage on Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $106.75.

Structure Therapeutics Trading Down 0.9%

NASDAQ GPCR opened at $42.93 on Friday. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of -49.34 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The stock has a 50-day moving average of $43.64 and a 200 day moving average of $57.18.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.